Tandem Diabetes (TNDM) Tops Q4 EPS by 8c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TNDM Hot Sheet
Join SI Premium – FREE
Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $290.4 million versus the consensus estimate of $276.75 million.
GUIDANCE:
Tandem Diabetes sees FY2026 revenue of $1.065-1.085 billion, versus the consensus of $1.102 billion.
For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chime Financial, Inc. (CHYM) Tops Q3 EPS by 13c ; Offers Guidance
- Fastly, Inc. (FSLY) Tops Q3 EPS by 5c, Offers Guidance
- Warrior Met Coal (HCC) Misses Q2 EPS by 58c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
